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The California Institute for Regenerative Medicine (CIRM) Alpha Stem Cell Clinic (ASCC) Network was
launched in 2015 to address a compelling unmet medical need for rigorous, FDA-regulated, stem cell-related
clinical trials for patients with challenging, incurable diseases. Here, we describe our multi-center experi-
ences addressing current and future challenges.Regenerative Medicine Challenges
and Opportunities
The goal of regenerative medicine is to
regenerate diseased or damaged patient
tissues with stem cells or related products.
Until recently, the evolving clinical regener-
ative medicine field was plagued by a
dearth of (1) systematic review of support-
ing pre-clinical evidence, (2) independent
reviewof safety andefficacybyappropriate
regulatory bodies, (3) trial-specific patient
education, and (4) collaborative manage-
ment of clinical trials to accelerate study
activation and access for a broad array of
patients. Other clinical trial challenges
include cellular therapy product-specific
manufacturing,delivery,andadministration
requirements and the need for long-term
follow up of patients. Numerous correlative
study biospecimens are also required to
satisfy rigorous regulatory requirements
(Kimmelman et al., 2016). The operational
complexity of and training required for
administering stem cell protocols has also
slowed study implementation. To address
these challenges and future hurdles, the
California Institute for Regenerative Medi-
cine (CIRM) Alpha Stem Cell Clinic (ASCC)
Network was established and recently
expanded as described below.
Meeting the Challenges through
Network Cooperation
Themajor challenges toward streamlined,
safe, and effective implementation ofregenerative medicine clinical trials can
be considered from the patient stand-
point, which include access, education,
and rapid inclusion in effective, regulated,
and rigorous trials. From the medical
personnel and regulatory perspective, it
includes having the requisite stem cell trial
training and rigorous adverse event re-
porting, biospecimen handling, and pro-
spective patient identification through
registries. From a scientific perspective,
it involves developing novel targeted ther-
apies that reproducibly enhance tissue
regeneration and repair. In general, a ma-
jor hurdle in clinical medicine is the rapid
dispatch of scientific discoveries from
the laboratory bench to the patient
bedside; this obstacle is amplified by
unique challenges in the emerging regen-
erative medicine field. While there is a
robust national Blood and Marrow Trans-
plant Clinical Research Network for
administration of hematopoietic cell prod-
ucts and a national marrow donor pro-
gram that provides a patient match regis-
try (Blood and Marrow Transplant Clinical
Research Network, NCT00023530)
(Walker et al., 2011), the networked imple-
mentation of other stem cell and regener-
ative medicine trials has not been ad-
dressed. In 2015, the first integrated
stem clinical network tasked with devel-
oping and implementing a panoply of
regenerative medicine trials was formed
by four leading California Medical CentersCell Stem Cel(UC San Diego, City of Hope, UC Los An-
geles, and UC Irvine) in partnership with
CIRM. In 2017, this network expanded
to include UC San Francisco/Benioff
Children’s Hospital and UC Davis. This
Network was funded by CIRM and institu-
tional commitments to accelerate delivery
of a diverse portfolio of stem cell therapies
(https://www.cirm.ca.gov/patients/alpha-
clinics-network) (Figure 1A). These clinics
operate independently while concomi-
tantly leveraging their respective institu-
tional assets and the collective power
of the network. Network priorities and
joint activities are determined by a
steering committee with oversight
from CIRM.
Organizational Challenges and
Opportunities
A delay in clinical trial activation resulting
from unique stem cell regulatory, con-
tracting, and coverage analysis require-
ments provided part of the impetus in
developing the ASCC Network (Table 1).
The clinics are only as good as the ability
of the parts to create an integrated
network. This is particularly challenging
across institutions because of the hetero-
geneity in type and breadth of clinical tri-
als being supported (Figure 1B). These tri-
als involve autologous and allogeneic
stem cell treatments as well as cancer
stem cell-targeting small molecules and
biologic therapeutic strategies alone orl 22, June 1, 2018 ª 2018 Elsevier Inc. 801
Figure 1. The CIRM Alpha Stem Cell Clinic (ASCC) Network and Clinical Trials
(A) CIRM ASCC Network and the disease indications.
(B) ASCC trials (n = 50) by disease indication.
(C) ASCC trials (n = 50) by cell type and indication. ‘‘Not applicable’’ indicates small-molecule, biologic, or non-cellular therapy.
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ASCC grants were awarded to institutions
in Southern California, including City of
Hope, UCLA/UC Irvine, and UC San
Diego. To enhance patient access
throughout California to stem cell-related
clinical trials, the ASCC Network was
expanded in 2017 to include UC San
Francisco/Benioff Children’s Hospital
and UC Davis. These areas were added
to enhance clinical trial accrual and
adherence by providing geographically
proximate treatment and/or follow-up for
patients in the San Francisco and Sacra-
mento metropolitan areas, where 30%
of the California population resides. In
addition, these sites maintain substantial
telemedicine infrastructure. Moreover,
some ASCC trials are expanding to sites
outside of the network and outside of Cal-
ifornia together with specific industry802 Cell Stem Cell 22, June 1, 2018sponsors. CIRM funding supports dedi-
cated teams within each center to coordi-
nate organizational resources in support
of specific stem cell trials’ needs . These
teams and the Network as a whole have
gained operational insights into effective
processing, testing, and multi-site deliv-
ery of novel investigational stem cell treat-
ments to patients.
The benefit of the Network and the
CIRM ASCC partnership is the ability to
rapidly implement and conduct more
robust clinical trials collectively rather
than independently. The number and di-
versity of trials create loop learning oppor-
tunities, which in turn drive innovation
across the Network. These innovations
combined with CIRM’s continuous fund-
ing pathways and pre-existing ASCC
Network capacities have resulted in coor-
dinated organizational synergy to accel-erate the development of stem cell
treatments.
The efficacy of this network approach
and organizational synergy is reflected in
direct feedback from commercial spon-
sors, who experienced product evalua-
tion at a faster than usual rate. For
example, CIRM partnered with Oncternal,
Inc. to support a Phase 1b/2 trial of Cirm-
tuzumab combined with Ibrutinib (Burger
et al., 2016, Rigolin et al., 2016) for refrac-
tory B cell malignancies and has applied
all aspects of the CIRM ASCC partnership
to this trial including a network-generated
IRB reliance agreement, accelerated
confidentiality agreement (CDA), and
accelerated clinical trial agreement
(CTA). Moreover, the first ASCC trial to
lead to an FDA-approved product is Yes-
carta (axicabtagene ciloleucel) (Neelapu
et al., 2017), an immunotherapeutic agent
Table 1. Clinical Trial Hurdles and Opportunities
Emerging Issue or Need Solution Status
Delays in initiating new sites due to IRB
review schedule
IRB Reliance Agreement Implemented for both clinical trial and
compassionate use protocols
Patient cohort identification and
recruitment
Using cohort finding and recruitment tools
UCRex and LADR
Cohort identification tool routinely used to
evaluate trial feasibility
Regulatory strategy and IND filings Develop teams with content area experts to
advise sponsors
ASCC sites and CIRM maintain internal
systems to conserve knowledge gained
from regulatory filing and processes
Appropriate facilities for product
manufacturing and/or processing for both
cell and/or gene therapy products
Leverage existing CIRM-supported
services and upgrade existing facilities
Three sites have GMP facilities; City of
Hope provides and UC Davis will expand
cell manufacturing services
Patient education and comprehensive
informed consent
Enhanced informed consent using tablet
devices where patients and families can
obtain information about their disease,
treatment, and other support services
Enhanced consent utilized in three
ASCC sites
Biospecimen handling and management Developed new standard operating
procedures for biospecimens
Capacity in place to manage all ASCC
patient visits monthly
Increasing access for patients Funding to support ASCCs at UC Davis
and UCSF/Oakland Children’s Hospital
Initial startup phase
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such as those for severe combined immu-
nodeficiency (SCID) (Schiroli et al., 2017),
spinal cord injury (Takahashi, 2018), and
hematologic malignancies (Abou-El-
Enein et al., 2017, Sessa et al., 2016)
have also experienced accelerated prod-
uct evaluation with CIRM ASCC
assistance.
Product Manufacturing and
Delivery
The ability to manufacture, process, and
deliver cells in a timely manner is a vital
feature of deploying effective stem cell
therapies. This aspect is thus a strong
focus of the Network, which supports a
variety of technology platforms ranging
across stem cell-expanded hematopoiet-
ic cell transplantation; brain or spinal cord
delivery of neural stem cells; retinal, liver,
lung, or cardiac delivery of stem cells;
infusion of chimeric antigen receptor
T cells; gene-modified progenitor cells;
and small molecules and biologics that
target stem cells. For example, one proto-
col requires patient screening and enroll-
ment at the UCLA clinic followed by
stem cell collection, genetic editing, and
infusion at the City of Hope site, and
then long-term follow-up at the referring
clinic.
Manufacturing capacity is bolstered
further by the IQVia Stem Cell Center,
which is a CIRM infrastructure-funded en-
tity to accelerate stem cell projects in the
pre-IND (investigational new drug) andpost-IND phases of cell product develop-
ment. The Center is an ASCC Network
partner and provides cell manufacturing,
clinical operations, regulatory, and phar-
maco-economic capabilities to the spon-
sors. This CIRM IQVia Stem Cell Center-
ASCC partnership can also enable spon-
sors to scale their manufacturing needs
to support the entire product develop-
ment life cycle.
Unique Patient Care Requirements
Pressing challenges for patients are ac-
cess to and adequate education about
appropriate regenerative medicine clin-
ical trials. Patient-focused teams at each
clinic disperse patient information about
trial education, trial enrollment, informed
consent, procedures, and follow-up visits.
Rapid patient education is required to
keep up with the substantial recent in-
crease in the number of clinical trials in
the Network; as of March 2018, 50 trials
in the key therapeutic areas of oncology,
hematology, ophthalmology, neurology,
cardiovascular disease, metabolic disor-
ders, and musculoskeletal disorders are
recruiting (Figure 1B), with many other tri-
als in the near-term clinical pipeline.
A particular challenge is the training of
nursing staff in the rapidly evolving stem
cell therapy field. This nursing expertise
is a critical aspect of successful stem
cell trial implementation and completion.
The CIRM ASCC Network sites have
been placed in existing clinical research
units or in separate nursing units; integra-tion of research nurseswith clinical nurses
is often necessary depending on the na-
ture of the stem cell therapy. The Network
has developed core competencies as well
as validation and inventory processes that
allow assessment of staff as needed.
Personnel dedicated to biospecimen
management work alongside nurses and
study coordinators to ensure that pro-
duct administration, clinical correlative
studies, and research procedures are per-
formed correctly and efficiently (Perrin
et al., 2018). To coordinate nurse activity,
the CIRM ASCC Network developed a
nursing role entitled ‘‘patient care coordi-
nator.’’ The patient care coordinator over-
sees the portfolio of stem cell therapies
and is responsible for ensuring that
nursing staff is adequately trained for
treatment and patient care management.
Simultaneously, the education of the
research subject and family is among
the nursing roles; the Network has devel-
oped stem cell-specific educational ma-
terials that serve to educate the study
participant and their caregivers and to
prevent non-compliancewith study-asso-
ciated medications. The ability of nurses
to coordinate specialized, complex
outpatient activities is paramount to safe
and efficient conduct of clinical trials.
Biospecimen Handling and Data
Science
The large number of biospecimens that
need to be collected for stem cell-related
trials to ensure both safety and long-ternCell Stem Cell 22, June 1, 2018 803
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lenge to clinical trial coordinators, as has
data entry and tracking of these
specimens.
ASCC trials represent a broad array of
cell therapies that often include special-
ized infusion or surgical procedures. To
support this, the ASCC has a Network-
wide patient registry and database. These
trials also require a large number of bio-
specimens, and autologous treatments
are particularly demanding. For example,
the clinic at the City of Hope averaged 66
patient visits and the handling of 344 bio-
specimens per month in the first quarter
of 2017. To support effective manage-
ment, processing, and mailing/delivery of
biospecimens, standard operating pro-
cedures and biospecimen coordinators
have been employed rather than relying
on clinical trial coordinators alone for bio-
specimen handling and data entry. Thus,
the ASCC is well positioned to contribute
to the data science initiatives that are be-
ing launched on a national level (https://
grants.nih.gov/grants/rfi/NIH-Strategic-
Plan-for-Data-Science.pdf).
An Evolving Regulatory Paradigm
The recent passage of the 21st Century
Cures Act and creation of the Regenera-
tive Medicine and Advanced Therapy
(RMAT) designation have established an
expedited pathway for stem cell and
regenerative medicine products (U.S.
Public Lab #114-255; 12/13/2016). Three
of the first 12 projects to obtain the
RMAT designation from the FDA were
CIRM programs. With regard to relevance
outside of California, the NIH has
launched the Regenerative Medicine
Initiative project as part of the 21st Cen-
tury Cures Act to accelerate, implement,
and develop regenerative medicine clin-
ical trials. CIRM and the ASCC Network
have developed mechanisms to ex-
change experiences that provide guid-
ance and can engage with content area
experts to advise on regulatory strategies.
For example, the ASCC provides support
to investigators on the regulatory issues
governing both pre-clinical and clinical
trial projects. Furthermore, CIRM main-
tains a clinical advisory panel (CAP) for
its clinical programs. Each CAP includes
CIRM scientific staff and external experts
in (1) the field research program, (2) cell
manufacturing, (3) regulatory sciences,
and (4) clinical operations. Importantly,804 Cell Stem Cell 22, June 1, 2018each CAP has a patient representative.
The CAP is designed to facilitate the
accelerated development of these pro-
grams, overcome obstacles, and provide
continuous consultation to the teams for
this innovative and relatively new product
development area. CIRM-funded trials in
the ASCC Network have utilized these
CAPs for extensive consultation on regu-
latory considerations specific to cell-
based treatments.
Operational Opportunities
Another key challenge is to accelerate
clinical research while supporting high-
quality and safe clinical trials particularly
for difficult-to-treat and/or rare diseases.
The Network has met this challenge by
instituting operational efficiencies and ac-
celeration tools as described below. Once
a project has IND approval and a protocol
has been submitted for review and
approval by the directors of each of the
ASCCs in the Network, the clinic sites
aspire to achieve first patient enrollment
in 90 days. An early priority has been the
development of tools to accelerate trial
initiation. These tools include (1) shared
non-disclosure agreements (NDAs) and
model CTAs, (2) an IRB reliance mecha-
nism whereby IRB approval by a single
institution in the ASCC is sufficient for
IRB approval at other Network sites that
would like to participate in the trial, (3)
large-scale (>25million patient lives) elec-
tronic medical records-based cohort-
finding and patient-recruitment registries
(e.g., University of California Research
eXchange, UCReX, and the Los Angeles
Data Resource, LADR), and (4) enhanced
(electronic) informed consent (eConsent)
tools. A collective marketing tool kit has
been developed whereby sponsors are
introduced to the Network and provided
with a preliminary feasibility assessment
in addition to a review of the availability
of manufacturing and/or processing facil-
ities. This feasibility assessment is facili-
tated by availability of a common Network
NDA.
The capacity to share clinical data and
documents in real time between the
ASCCs has proven pivotal for overcoming
hurdles blocking study initiation and
conduct. UCLA took the lead in building
an IRB reliance agreement between
ASCC sites. Currently, all stem cell trials
conducted at the ASCCs have been re-
viewed and authorized by the FDA andare approved andmonitored by the clinic’s
research ethics committee. All sites have
entered into a reliance agreementwhereby
IRB review (including RMAT designation
with FDA guidance) can be delegated to
a lead site. Other Network sites can then
rely on the lead IRB review to initiate trials
more quickly. For example, one gene-
transfer therapy protocol requires 9 weeks
of monitoring from screening to infusion,
with continual patient follow-up over a
48-week period. Patients are typically not
familiar with the clinical workup, apheresis,
and processing procedures or concomi-
tant risks; therefore, informed consent
must be dynamic and robust. To support
robust consent, the Network developed
enhancedelectronic consent utilizing elec-
tronic tablet devices. Such enhanced con-
sent has been utilized in three ASCC trials;
patients and families find them easy to ac-
cess and simple to use.
The successof theNetwork relies onob-
taining sustainable funding and clinical
expertise as well as enhancing data and
operational systems developed through
the ASCC Network that will contribute to
therapeutic practice standards and help
to guide future regenerative medicine
efforts. Clinical trials in the network
are increasingly industry sponsored:
leveraging of ASCC resources promotes
efficiency and increases the chance of in-
dustry-sponsored clinical trial success.
The ASCCNetwork has gained key opera-
tional insights and developed strategies to
overcome roadblocks that hinder process-
ing, testing, and delivery of investigational
stem cell therapies. Future opportunities
for the ASCC Network are in broadening
the pipeline of regenerative medicine ther-
apies and enhancing its geographic reach
via telemedicine to reduce the cost associ-
atedwith patient screening, follow-up, and
adherence.Another futuregoal is acentral-
ized patient registry. By connecting to and
leveraging emerging data science efforts,
there is great potential to enable stem cell
clinical research on a more global scale
and to provide healthcare economics
data that would support payment models
and enable access to these treatments.
Going forward, it is anticipated that chal-
lenges posed in the arena of stemcell ther-
apeutics will bemet in creative partnership
with CIRM, its ASCC Network, industry
partners, and the Regenerative Medicine
Innovation Project at theNIH.While unique
regulatory requirements and availability of
Cell Stem Cell
Forumacademic, philanthropic, and industry
sponsorship may limit access to stem
cell-related clinical trials in other areas,
theASCCNetwork providesapivotal para-
digm for establishing rigorously regulated
stemcell clinical trials in a largegeographic
area. This paradigmcould be implemented
outside of the state of California as well as
in other countries.
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